Ligand Pharmaceuticals的合作伙伴Sq Innovation宣布，其产品Lasix® Onyu已获得美国食品药品监督管理局（FDA）的批准。该产品是一款专门针对心力衰竭患者水肿症状的居家治疗方案。
这一批准标志着心衰患者在管理水肿症状方面迈出了重要一步，使患者能够在家中便捷地接受治疗，无需频繁前往医疗机构。Lasix® Onyu为心力衰竭患者提供了更加灵活和便利的治疗选择。
Ligand Pharmaceuticals的合作伙伴Sq Innovation宣布，其产品Lasix® Onyu已获得美国食品药品监督管理局（FDA）的批准。该产品是一款专门针对心力衰竭患者水肿症状的居家治疗方案。
这一批准标志着心衰患者在管理水肿症状方面迈出了重要一步，使患者能够在家中便捷地接受治疗，无需频繁前往医疗机构。Lasix® Onyu为心力衰竭患者提供了更加灵活和便利的治疗选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.